Array and Pfizer's initial focus is to test drug combos in a phase 1b trial in non-small cell lung cancer and pancreatic cancer.

The agreement positions Cochlear to expand beyond hearing-loss devices by licensing the therapeutic if it impresses in development.

The project is built upon a device Rani designed to enable the oral delivery of proteins and other molecules that are currently injected.

Success against the primary endpoint in the pivotal trial sets Akili up to file for FDA approval of the digital medicine.

Stratasys' new BioMimics service overcomes problems with current medical device testing and physician training methods.

Just days after their lead drug-device combination was voted down by FDA advisors, Nektar and Bayer were hit by a phase 3 failure in another program.

The National Health Service of England is scaling up a program to detect lung cancer earlier and also unveiled a new test to catch bowel cancer.

Lilly is working on devices that move it onto Medtronic’s turf and has teamed up with Dexcom to add continuous glucose monitoring to its arsenal.